Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
10.36
USD
|
-0.29%
|
|
-5.65%
|
-7.75%
|
Fiscal Period: März |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
502.1
|
3,419
|
5,597
|
7,653
|
-
|
-
|
Enterprise Value (EV)
1 |
502.1
|
1,568
|
5,597
|
8,494
|
2,927
|
4,015
|
P/E ratio
|
-2.6
x
|
-3.92
x
|
-5.2
x
|
2.02
x
|
-9.21
x
|
-7.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
61.8
x
|
91.3
x
|
68.1
x
|
55.5
x
|
28.5
x
|
EV / Revenue
|
-
|
28.4
x
|
91.3
x
|
68.1
x
|
21.2
x
|
14.9
x
|
EV / EBITDA
|
-
|
-1.17
x
|
-4.84
x
|
-7.83
x
|
-2.8
x
|
-4.17
x
|
EV / FCF
|
-
|
-
|
-
|
-2.08
x
|
-2.64
x
|
-3.76
x
|
FCF Yield
|
-
|
-
|
-
|
-48.1%
|
-37.8%
|
-26.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
51,340
|
692,072
|
758,427
|
738,722
|
-
|
-
|
Reference price
2 |
9.780
|
4.940
|
7.380
|
10.36
|
10.36
|
10.36
|
Announcement Date
|
7/1/21
|
6/28/22
|
6/28/23
|
5/30/24
|
-
|
-
|
Fiscal Period: März |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
55.29
|
61.28
|
124.8
|
137.8
|
268.6
|
EBITDA
1 |
-
|
-1,346
|
-1,156
|
-1,084
|
-1,044
|
-962.5
|
EBIT
1 |
-
|
-1,352
|
-1,175
|
-1,106
|
-1,081
|
-1,032
|
Operating Margin
|
-
|
-2,444.82%
|
-1,917.95%
|
-886.57%
|
-784.77%
|
-384.32%
|
Earnings before Tax (EBT)
1 |
-
|
-923.7
|
-1,225
|
4,253
|
-917.9
|
-997.2
|
Net income
1 |
-809.2
|
-845.3
|
-1,009
|
4,349
|
-793.2
|
-881.7
|
Net margin
|
-
|
-1,528.89%
|
-1,646.59%
|
3,484.86%
|
-575.71%
|
-328.28%
|
EPS
2 |
-3.760
|
-1.260
|
-1.420
|
5.230
|
-1.125
|
-1.307
|
Free Cash Flow
1 |
-
|
-
|
-
|
-962.5
|
-1,107
|
-1,067
|
FCF margin
|
-
|
-
|
-
|
-145.47%
|
-803.63%
|
-397.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/1/21
|
6/28/22
|
6/28/23
|
5/30/24
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
13.99
|
24.34
|
9.223
|
4.319
|
12.53
|
17.05
|
27.38
|
21.62
|
37.1
|
37.14
|
28.93
|
53.26
|
33.3
|
36.99
|
40.98
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-280.8
|
-378.1
|
-228.2
|
-270.6
|
-270.9
|
-282.1
|
-260.8
|
-
|
-
|
-
|
-
|
EBIT
1 |
-684.4
|
-246
|
-266.8
|
-282.3
|
-280.8
|
-378.1
|
-234.2
|
-276.4
|
-276.5
|
5,061
|
-266
|
-268
|
-270.8
|
-273.3
|
-259.7
|
Operating Margin
|
-4,893.32%
|
-1,010.73%
|
-2,892.8%
|
-6,536.44%
|
-2,240.21%
|
-2,217.2%
|
-855.37%
|
-1,278.27%
|
-745.14%
|
13,626.5%
|
-919.46%
|
-503.31%
|
-813.09%
|
-738.95%
|
-633.73%
|
Earnings before Tax (EBT)
1 |
-225.2
|
-306
|
-291.5
|
-349.8
|
-313.8
|
-382.1
|
-179.2
|
-326.1
|
-327.4
|
5,098
|
-191.5
|
-201.4
|
-210.5
|
-220.9
|
-231.9
|
Net income
1 |
-208.5
|
-284.5
|
-270.1
|
-331.8
|
-291.6
|
-352
|
-33.62
|
-291.8
|
-304.3
|
5,096
|
-151.1
|
-171.9
|
-208.8
|
-219.8
|
-234.9
|
Net margin
|
-1,490.53%
|
-1,168.96%
|
-2,928.14%
|
-7,682.54%
|
-2,326.58%
|
-2,064.36%
|
-122.8%
|
-1,349.5%
|
-820.27%
|
13,721.55%
|
-522.35%
|
-322.69%
|
-627.1%
|
-594.29%
|
-573.15%
|
EPS
2 |
-0.3200
|
-0.4100
|
-0.3900
|
-0.4800
|
-0.4200
|
-0.4900
|
-0.0500
|
-0.3800
|
-0.4000
|
6.030
|
-0.1900
|
-0.3020
|
-0.3160
|
-0.3360
|
-0.3320
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
2/14/22
|
6/28/22
|
8/15/22
|
11/14/22
|
2/13/23
|
6/28/23
|
8/14/23
|
11/13/23
|
2/13/24
|
5/30/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1,850
|
-
|
5,652
|
4,726
|
3,638
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-963
|
-1,107
|
-1,067
|
ROE (net income / shareholders' equity)
|
-
|
-48.9%
|
-
|
123%
|
-10.8%
|
-33.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-40.6%
|
95.7%
|
-21.3%
|
-25.2%
|
Assets
1 |
-
|
-
|
2,487
|
4,452
|
3,724
|
3,499
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
5.660
|
-1.070
|
-0.8900
|
Capex
1 |
-
|
17.4
|
-
|
4.39
|
5.91
|
6.37
|
Capex / Sales
|
-
|
31.54%
|
-
|
0.66%
|
4.29%
|
2.37%
|
Announcement Date
|
7/1/21
|
6/28/22
|
6/28/23
|
5/30/24
|
-
|
-
|
Last Close Price
10.36
USD Average target price
16.78
USD Spread / Average Target +61.95% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.75% | 7.65B | | +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | -5.52% | 206B | | +6.17% | 164B | | -0.45% | 162B |
Other Pharmaceuticals
|